董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sarah B. Noonberg | 女 | Director | 53 | 28.48万美元 | 未持股 | 2021-03-16 |
| M. Cantey Boyd | 女 | Director | 41 | 28.24万美元 | 未持股 | 2021-03-16 |
| Jonathan G. Drachman | 男 | Director, Chief Executive Officer and President | 59 | 446.85万美元 | 未持股 | 2021-03-16 |
| Erin Lavelle | 女 | Director | 43 | 54.09万美元 | 未持股 | 2021-03-16 |
| Martin Babler | 男 | Director | 56 | 47.94万美元 | 未持股 | 2021-03-16 |
| Lewis T. Williams | 男 | Director | 71 | 29.34万美元 | 未持股 | 2021-03-16 |
| Todd Simpson | 男 | Director, Chairman of the Board | 60 | 32.12万美元 | 未持股 | 2021-03-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan G. Drachman | 男 | Director, Chief Executive Officer and President | 59 | 446.85万美元 | 未持股 | 2021-03-16 |
| Robert Ho | 男 | Chief Financial Officer | 45 | 265.43万美元 | 未持股 | 2021-03-16 |
| Holly Vance | 女 | General Counsel and Secretary | 46 | 209.18万美元 | 未持股 | 2021-03-16 |
| Carl Walkey | 男 | Senior Vice President of Corporate Development | 36 | 未披露 | 未持股 | 2021-03-16 |
董事简历
中英对照 | 中文 | 英文- Sarah B. Noonberg
-
SarahB.Noonberg于2018年5月至2019年5月担任Nohla Therapeutics Inc.的首席医疗官，该公司是一家为血液恶性肿瘤和其他危重疾病患者开发通用的现成细胞疗法的开发商。在加入Nohla Therapeutics之前，她曾于2017年5月至2018年3月担任生物技术公司Prothena Corporation plc的首席医疗官。在加入Prothena之前，Noonberg博士于2015年8月至2017年3月担任生物技术公司BioMarin Pharmaceuticals Inc.的集团Vice President兼全球临床开发主管。2007年5月至2015年8月，她在生物制药公司Medivation，Inc.担任多个职位，最终担任早期开发高级副总裁。她目前在ProtagonistTherapeutics，Inc.的董事会任职。Noonberg博士在加州大学旧金山分校（University of California，San Francisco）获得医学博士学位，在加州大学伯克利分校（University of California，Berkeley）获得生物工程博士学位，在达特茅斯学院（Dartmouth College）获得工程学学士学位。她是董事会认证的内科医生，并完成了Johns Hopkins Hospital的住院医师资格。
Sarah B. Noonberg is the Chief Medical Officer of Maze Therapeutics. Previously, Dr. Noonberg served as the Chief Medical Officer of Nohla Therapeutics Inc., a developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, from May 2018 to May 2019. Prior to joining Nohla Therapeutics, she served as the Chief Medical Officer of Prothena Corporation plc, a biotechnology company, from May 2017 to March 2018. Prior to joining Prothena, Dr. Noonberg served as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc., a biotechnology company, from August 2015 to March 2017. From May 2007 to August 2015 she held several positions at Medivation, Inc., a biopharmaceutical company, culminating in the position of Senior Vice President of Early Development. She currently serves on the board of directors of Protagonist Therapeutics, Inc. Dr. Noonberg received her M.D. at the University of California, San Francisco, her Ph.D. in Bioengineering at the University of California, Berkeley, and her B.S. in Engineering at Dartmouth College. She is a board-certified internist and completed her residency at Johns Hopkins Hospital. - SarahB.Noonberg于2018年5月至2019年5月担任Nohla Therapeutics Inc.的首席医疗官，该公司是一家为血液恶性肿瘤和其他危重疾病患者开发通用的现成细胞疗法的开发商。在加入Nohla Therapeutics之前，她曾于2017年5月至2018年3月担任生物技术公司Prothena Corporation plc的首席医疗官。在加入Prothena之前，Noonberg博士于2015年8月至2017年3月担任生物技术公司BioMarin Pharmaceuticals Inc.的集团Vice President兼全球临床开发主管。2007年5月至2015年8月，她在生物制药公司Medivation，Inc.担任多个职位，最终担任早期开发高级副总裁。她目前在ProtagonistTherapeutics，Inc.的董事会任职。Noonberg博士在加州大学旧金山分校（University of California，San Francisco）获得医学博士学位，在加州大学伯克利分校（University of California，Berkeley）获得生物工程博士学位，在达特茅斯学院（Dartmouth College）获得工程学学士学位。她是董事会认证的内科医生，并完成了Johns Hopkins Hospital的住院医师资格。
- Sarah B. Noonberg is the Chief Medical Officer of Maze Therapeutics. Previously, Dr. Noonberg served as the Chief Medical Officer of Nohla Therapeutics Inc., a developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, from May 2018 to May 2019. Prior to joining Nohla Therapeutics, she served as the Chief Medical Officer of Prothena Corporation plc, a biotechnology company, from May 2017 to March 2018. Prior to joining Prothena, Dr. Noonberg served as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc., a biotechnology company, from August 2015 to March 2017. From May 2007 to August 2015 she held several positions at Medivation, Inc., a biopharmaceutical company, culminating in the position of Senior Vice President of Early Development. She currently serves on the board of directors of Protagonist Therapeutics, Inc. Dr. Noonberg received her M.D. at the University of California, San Francisco, her Ph.D. in Bioengineering at the University of California, Berkeley, and her B.S. in Engineering at Dartmouth College. She is a board-certified internist and completed her residency at Johns Hopkins Hospital.
- M. Cantey Boyd
-
M.Cantey Boyd是贝克兄弟投资公司（Baker Brothers Investments）的董事总经理，该公司是一家注册投资顾问公司，专注于生命科学公司的长期投资。在2005年加入Baker Brothers之前，Boyd女士从2002年到2004年是Deutsche Bank Securities的梦百合投资银行集团的分析师。Boyd女士毕业于布朗大学（Brown University）商业经济学学士学位。
M. Cantey Boyd is a Managing Director at Baker Brothers Investments, a registered investment adviser focused on long-term investments in life-sciences companies. Prior to joining Baker Brothers in 2005 Ms. Boyd was an Analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. Ms. Boyd graduated with an A.B. in Business-Economics from Brown University. - M.Cantey Boyd是贝克兄弟投资公司（Baker Brothers Investments）的董事总经理，该公司是一家注册投资顾问公司，专注于生命科学公司的长期投资。在2005年加入Baker Brothers之前，Boyd女士从2002年到2004年是Deutsche Bank Securities的梦百合投资银行集团的分析师。Boyd女士毕业于布朗大学（Brown University）商业经济学学士学位。
- M. Cantey Boyd is a Managing Director at Baker Brothers Investments, a registered investment adviser focused on long-term investments in life-sciences companies. Prior to joining Baker Brothers in 2005 Ms. Boyd was an Analyst in the Healthcare Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. Ms. Boyd graduated with an A.B. in Business-Economics from Brown University.
- Jonathan G. Drachman
-
JonathanG.Drachman自2018年11月起担任Neoleukin的董事兼首席执行官。从2004年11月到2018年5月，Drachman博士在SeattleGenetics，Inc.担任过多个职位，最终担任研究与开发首席医疗官兼执行Vice President。从1998年到2004年，他曾担任华盛顿大学（University of Washington）的血液学部门的教员，以及普吉特海湾血液中心（Puget Sound Blood Center）的研究和教育部门的高级研究员。他目前任职于HarpoonTherapeutics，Inc.和CalitheraBiosciences，Inc.的董事会。Drachman博士在哈佛医学院（Harvard Medical School）获得医学博士学位，并在哈佛学院（Harvard College）获得生物化学学士学位。他在华盛顿大学（University of Washington）完成内科住院医师和医疗肿瘤学研究金。
Jonathan G. Drachman has served as a director and the Chief Executive Officer of Neoleukin since November 2018. From November 2004 to May 2018 Dr. Drachman held several positions at Seagen Inc., culminating in the position of Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004 he was a faculty member in the Division of Hematology at the University of Washington, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors of Harpoon Therapeutics, Inc. and Calithera Biosciences, Inc. Dr. Drachman received his M.D. at Harvard Medical School and his A.B. in Biochemistry from Harvard College. He completed his residency in internal medicine and a fellowship in medical oncology at the University of Washington. - JonathanG.Drachman自2018年11月起担任Neoleukin的董事兼首席执行官。从2004年11月到2018年5月，Drachman博士在SeattleGenetics，Inc.担任过多个职位，最终担任研究与开发首席医疗官兼执行Vice President。从1998年到2004年，他曾担任华盛顿大学（University of Washington）的血液学部门的教员，以及普吉特海湾血液中心（Puget Sound Blood Center）的研究和教育部门的高级研究员。他目前任职于HarpoonTherapeutics，Inc.和CalitheraBiosciences，Inc.的董事会。Drachman博士在哈佛医学院（Harvard Medical School）获得医学博士学位，并在哈佛学院（Harvard College）获得生物化学学士学位。他在华盛顿大学（University of Washington）完成内科住院医师和医疗肿瘤学研究金。
- Jonathan G. Drachman has served as a director and the Chief Executive Officer of Neoleukin since November 2018. From November 2004 to May 2018 Dr. Drachman held several positions at Seagen Inc., culminating in the position of Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004 he was a faculty member in the Division of Hematology at the University of Washington, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors of Harpoon Therapeutics, Inc. and Calithera Biosciences, Inc. Dr. Drachman received his M.D. at Harvard Medical School and his A.B. in Biochemistry from Harvard College. He completed his residency in internal medicine and a fellowship in medical oncology at the University of Washington.
- Erin Lavelle
-
Erin Lavelle自2020年10月起担任首席运营官兼首席财务官Eliem Therapeutics，这是一家总部位于西雅图的私营神经治疗公司。Lavelle女士于2018年4月至2020年2月担任AlderBiopharmaceuticals，Inc.首席运营官此外，她曾担任Vitaeris公司（私人生物技术公司，位于加拿大British Columbia温哥华）的Alder公司的任命董事。在此之前，她于2003年至2018年在安进公司担任过各种职务，最近于2017年9月至2018年4月担任台湾总经理，于2016年5月至2017年9月担任日本亚太香港执行董事，2014年6月至2016年5月的全球营销业务分析和见解。她的职业生涯始于美林投资银行。Lavelle女士拥有耶鲁大学经济学学士学位。
Erin Lavelle has served as the Chief Operating Officer and Chief Financial Officer Eliem Therapeutics, a Seattle-based privately held neurological therapeutics company, since October 2020. From April 2018 to February 2020 Ms. Lavelle served as the Chief Operating Officer at Alder BioPharmaceuticals, Inc. In addition to that role, she served as Alder’s appointed director for Vitaeris Inc., a privately held biotechnology company based in Vancouver, British Columbia, Canada. Prior to that, she served in various roles at Amgen Inc. from 2003 to 2018 most recently serving as General Manager Taiwan from September 2017 to April 2018 as Executive Director, Japan Asia Pacific Hong Kong from May 2016 to September 2017 and Executive Director, Global Marketing Business Analytics and Insights from June 2014 to May 2016. She started her career in Investment Banking at Merrill Lynch. Ms. Lavelle holds a Bachelor of Arts in Economics from Yale University. - Erin Lavelle自2020年10月起担任首席运营官兼首席财务官Eliem Therapeutics，这是一家总部位于西雅图的私营神经治疗公司。Lavelle女士于2018年4月至2020年2月担任AlderBiopharmaceuticals，Inc.首席运营官此外，她曾担任Vitaeris公司（私人生物技术公司，位于加拿大British Columbia温哥华）的Alder公司的任命董事。在此之前，她于2003年至2018年在安进公司担任过各种职务，最近于2017年9月至2018年4月担任台湾总经理，于2016年5月至2017年9月担任日本亚太香港执行董事，2014年6月至2016年5月的全球营销业务分析和见解。她的职业生涯始于美林投资银行。Lavelle女士拥有耶鲁大学经济学学士学位。
- Erin Lavelle has served as the Chief Operating Officer and Chief Financial Officer Eliem Therapeutics, a Seattle-based privately held neurological therapeutics company, since October 2020. From April 2018 to February 2020 Ms. Lavelle served as the Chief Operating Officer at Alder BioPharmaceuticals, Inc. In addition to that role, she served as Alder’s appointed director for Vitaeris Inc., a privately held biotechnology company based in Vancouver, British Columbia, Canada. Prior to that, she served in various roles at Amgen Inc. from 2003 to 2018 most recently serving as General Manager Taiwan from September 2017 to April 2018 as Executive Director, Japan Asia Pacific Hong Kong from May 2016 to September 2017 and Executive Director, Global Marketing Business Analytics and Insights from June 2014 to May 2016. She started her career in Investment Banking at Merrill Lynch. Ms. Lavelle holds a Bachelor of Arts in Economics from Yale University.
- Martin Babler
-
Martin Babler，2008年5月以来，他担任我们的董事会的成员。2011年4月以来，他成为Principia BioPharma, Inc.（一个刚刚起步的公司，开发自身免疫性疾病的新药物）的首席执行官和董事。从2008年2月到2011年4月，他担任 Talima Therapeutics, Inc.（云网络公司）的首席执行官。加入Talima之前的2000年到2006年，他曾是基因泰克（Genentech）（一个上市的生物制药公司）免疫学销售和营销和心血管市场营销董事。加入基因泰克（Genentech）之前，他担任Eli Lilly and Compan的各种销售、销售管理、营销和业务拓展的职务，并不断被提拔。他获得瑞士联邦理工学院（ the Swiss Federal Institute of Technology）的药剂学/药物学学位并进入凯洛格管理研究所（ Kellogg Graduate School of Management）进行主管发展项目（Executive Development Program ）学习。
Martin Babler served as President and Chief Executive Officer at Principia Biopharma Inc., a biopharmaceutical company, from April 2011 until its acquisition by Sanofi S.A. in October 2020. From December 2007 to April 2011 Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007 Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. Mr. Babler was previously employed at Eli Lilly and Company, a pharmaceutical company, in positions focused on sales, sales management, global marketing and business development. Mr. Babler presently serves on the board of directors of Omega Alpha SPAC and on the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization, or BIO. Mr. Babler received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University. - Martin Babler，2008年5月以来，他担任我们的董事会的成员。2011年4月以来，他成为Principia BioPharma, Inc.（一个刚刚起步的公司，开发自身免疫性疾病的新药物）的首席执行官和董事。从2008年2月到2011年4月，他担任 Talima Therapeutics, Inc.（云网络公司）的首席执行官。加入Talima之前的2000年到2006年，他曾是基因泰克（Genentech）（一个上市的生物制药公司）免疫学销售和营销和心血管市场营销董事。加入基因泰克（Genentech）之前，他担任Eli Lilly and Compan的各种销售、销售管理、营销和业务拓展的职务，并不断被提拔。他获得瑞士联邦理工学院（ the Swiss Federal Institute of Technology）的药剂学/药物学学位并进入凯洛格管理研究所（ Kellogg Graduate School of Management）进行主管发展项目（Executive Development Program ）学习。
- Martin Babler served as President and Chief Executive Officer at Principia Biopharma Inc., a biopharmaceutical company, from April 2011 until its acquisition by Sanofi S.A. in October 2020. From December 2007 to April 2011 Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007 Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. Mr. Babler was previously employed at Eli Lilly and Company, a pharmaceutical company, in positions focused on sales, sales management, global marketing and business development. Mr. Babler presently serves on the board of directors of Omega Alpha SPAC and on the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization, or BIO. Mr. Babler received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
- Lewis T. Williams
-
LewisT.Williams自2017年6月起担任董事会成员。他自2019年2月起担任生物技术初创公司Walking Fish Therapeutics的董事长兼首席执行官。Williams博士自2018年10月起还担任专注于梦百合的风险投资公司Quan Capital，LLP的风险合伙人。Williams博士于2002年1月至2020年1月创立上市生物技术公司Five PrimeTherapeutics，Inc.并担任其董事，并于2011年4月至2017年12月担任其总裁兼首席执行官。此前，Williams博士在Chiron Corporation“Chiron”（一家生物制药公司，现称为Novartis Vaccines and Diagnostics，Inc.）任职七年，最近担任其首席科学官。他也曾任职Chiron公司的董事会（1999年至2001年）。在加入Chiron之前，Williams博士是加州大学旧金山分校（University of California，San Francisco）的医学教授，并担任该大学心血管研究机构和第一研究中心的主任。Williams博士还曾在哈佛医学院（Harvard Medical School）和马萨诸塞州总医院（Massachusetts General Hospital）的院系任职，并联合创立了COR Therapeutics，Inc.，这是一家专注于心血管疾病的生物技术公司。他是美国国家科学院（National Academy of Sciences）的成员，以及美国艺术与科学院（American Academy of Arts and Sciences）的院士。Williams博士自2019年9月起担任公共生物制药公司Neoleukin Pharmaceuticals的董事会成员。他之前是COR Therapeutics，Inc.和BeckmanCoulter，Inc.的董事会成员，这两家公司在他担任董事期间都是一家上市公司。Williams博士目前还在一家私人控股公司的董事会任职。他在莱斯大学（Rice University）获得学士学位，在杜克大学（Duke University）获得医学博士学位和博士学位。
Lewis T. Williams has served as the Chairman and Chief Executive Officer of Walking Fish Therapeutics, Inc., a biotechnology start-up company, since February 2019. Dr. Williams has also served as a venture partner of Quan Capital, LLP, a healthcare-focused venture capital firm, since October 2018. From January 2002 to December 2017 Dr. Williams founded and held several positions at Five Prime Therapeutics, Inc., culminating in the position of President and Chief Executive Officer from April 2011 to December 2017. From September 1992 to December 2001 Dr. Williams held several positions at Chiron Corporation, culminating in the position as Chief Scientific Officer and as a member of the board of directors. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco from August 1984 to June 1993 where he served as the director of the Cardiovascular Research Institution and Daiichi Research Center. Prior to UCSF, Dr. Williams co-founded and served on the board of directors of COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease, from June 1989 to September 1994 and served on the faculties of Harvard Medical School and Massachusetts General Hospital from July 1982 to July 1984. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams received his B.S. in Chemistry from Rice University, and his M.D. and Ph.D. in Pharmacology / Biochemistry from Duke University. - LewisT.Williams自2017年6月起担任董事会成员。他自2019年2月起担任生物技术初创公司Walking Fish Therapeutics的董事长兼首席执行官。Williams博士自2018年10月起还担任专注于梦百合的风险投资公司Quan Capital，LLP的风险合伙人。Williams博士于2002年1月至2020年1月创立上市生物技术公司Five PrimeTherapeutics，Inc.并担任其董事，并于2011年4月至2017年12月担任其总裁兼首席执行官。此前，Williams博士在Chiron Corporation“Chiron”（一家生物制药公司，现称为Novartis Vaccines and Diagnostics，Inc.）任职七年，最近担任其首席科学官。他也曾任职Chiron公司的董事会（1999年至2001年）。在加入Chiron之前，Williams博士是加州大学旧金山分校（University of California，San Francisco）的医学教授，并担任该大学心血管研究机构和第一研究中心的主任。Williams博士还曾在哈佛医学院（Harvard Medical School）和马萨诸塞州总医院（Massachusetts General Hospital）的院系任职，并联合创立了COR Therapeutics，Inc.，这是一家专注于心血管疾病的生物技术公司。他是美国国家科学院（National Academy of Sciences）的成员，以及美国艺术与科学院（American Academy of Arts and Sciences）的院士。Williams博士自2019年9月起担任公共生物制药公司Neoleukin Pharmaceuticals的董事会成员。他之前是COR Therapeutics，Inc.和BeckmanCoulter，Inc.的董事会成员，这两家公司在他担任董事期间都是一家上市公司。Williams博士目前还在一家私人控股公司的董事会任职。他在莱斯大学（Rice University）获得学士学位，在杜克大学（Duke University）获得医学博士学位和博士学位。
- Lewis T. Williams has served as the Chairman and Chief Executive Officer of Walking Fish Therapeutics, Inc., a biotechnology start-up company, since February 2019. Dr. Williams has also served as a venture partner of Quan Capital, LLP, a healthcare-focused venture capital firm, since October 2018. From January 2002 to December 2017 Dr. Williams founded and held several positions at Five Prime Therapeutics, Inc., culminating in the position of President and Chief Executive Officer from April 2011 to December 2017. From September 1992 to December 2001 Dr. Williams held several positions at Chiron Corporation, culminating in the position as Chief Scientific Officer and as a member of the board of directors. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco from August 1984 to June 1993 where he served as the director of the Cardiovascular Research Institution and Daiichi Research Center. Prior to UCSF, Dr. Williams co-founded and served on the board of directors of COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease, from June 1989 to September 1994 and served on the faculties of Harvard Medical School and Massachusetts General Hospital from July 1982 to July 1984. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams received his B.S. in Chemistry from Rice University, and his M.D. and Ph.D. in Pharmacology / Biochemistry from Duke University.
- Todd Simpson
-
Todd Simpson，自2014年1月起担任本公司董事。自2005年10月起，他担任生物技术公司Seattle Genetics的首席财务官。此前，从2001年10月至2005年10月，他担任生物技术公司Targeted Genetics Corporation的财务与行政副总裁、首席财务官。从1996年1月至2001年10月，他担任生物技术公司 Aastrom Biosciences的财务与行政副总裁、首席财务官。从1995年8月至1995年12月，他担任生物技术公司Integra LifeSciences Corporation的财务总管，该公司在1995年8月收购了Telios Pharmaceuticals。从1992年起，他担任 Telios 的财务副总裁和首席财务官，以及其它财务相关的职务，直到被它被Integra收购。他目前是华盛顿生物技术和生物医学协会董事会的执行委员会成员。他是一名注册会计师，于1983-1992年间，在安永会计师事务所从事公共执业。他获得了俄勒冈州立大学的会计与计算机学士学位。
Todd Simpson has served as the Chief Financial Officer of Seagen Inc., a biotechnology company, since October 2005. Previously, Mr. Simpson served from October 2001 to October 2005 as Vice President, Finance & Administration and Chief Financial Officer of Targeted Genetics Corporation, a biotechnology company. From January 1996 to October 2001 Mr. Simpson served as Vice President, Finance & Administration and Chief Financial Officer of Aastrom Biosciences, Inc., a biotechnology company. From August 1995 to December 1995 he served as Treasurer of Integra LifeSciences Corporation, a biotechnology company, which acquired Telios Pharmaceuticals, Inc., in August 1995. From 1992 until its acquisition by Integra, he served as Vice President of Finance and Chief Financial Officer of Telios and in various other finance-related positions. Mr. Simpson is a certified public accountant inactive, and from 1983 to 1992 he practiced public accounting with the firm of Ernst & Young LLP. Mr. Simpson received a B.S. in Accounting and Computer Science from Oregon State University. - Todd Simpson，自2014年1月起担任本公司董事。自2005年10月起，他担任生物技术公司Seattle Genetics的首席财务官。此前，从2001年10月至2005年10月，他担任生物技术公司Targeted Genetics Corporation的财务与行政副总裁、首席财务官。从1996年1月至2001年10月，他担任生物技术公司 Aastrom Biosciences的财务与行政副总裁、首席财务官。从1995年8月至1995年12月，他担任生物技术公司Integra LifeSciences Corporation的财务总管，该公司在1995年8月收购了Telios Pharmaceuticals。从1992年起，他担任 Telios 的财务副总裁和首席财务官，以及其它财务相关的职务，直到被它被Integra收购。他目前是华盛顿生物技术和生物医学协会董事会的执行委员会成员。他是一名注册会计师，于1983-1992年间，在安永会计师事务所从事公共执业。他获得了俄勒冈州立大学的会计与计算机学士学位。
- Todd Simpson has served as the Chief Financial Officer of Seagen Inc., a biotechnology company, since October 2005. Previously, Mr. Simpson served from October 2001 to October 2005 as Vice President, Finance & Administration and Chief Financial Officer of Targeted Genetics Corporation, a biotechnology company. From January 1996 to October 2001 Mr. Simpson served as Vice President, Finance & Administration and Chief Financial Officer of Aastrom Biosciences, Inc., a biotechnology company. From August 1995 to December 1995 he served as Treasurer of Integra LifeSciences Corporation, a biotechnology company, which acquired Telios Pharmaceuticals, Inc., in August 1995. From 1992 until its acquisition by Integra, he served as Vice President of Finance and Chief Financial Officer of Telios and in various other finance-related positions. Mr. Simpson is a certified public accountant inactive, and from 1983 to 1992 he practiced public accounting with the firm of Ernst & Young LLP. Mr. Simpson received a B.S. in Accounting and Computer Science from Oregon State University.
高管简历
中英对照 | 中文 | 英文- Jonathan G. Drachman
JonathanG.Drachman自2018年11月起担任Neoleukin的董事兼首席执行官。从2004年11月到2018年5月，Drachman博士在SeattleGenetics，Inc.担任过多个职位，最终担任研究与开发首席医疗官兼执行Vice President。从1998年到2004年，他曾担任华盛顿大学（University of Washington）的血液学部门的教员，以及普吉特海湾血液中心（Puget Sound Blood Center）的研究和教育部门的高级研究员。他目前任职于HarpoonTherapeutics，Inc.和CalitheraBiosciences，Inc.的董事会。Drachman博士在哈佛医学院（Harvard Medical School）获得医学博士学位，并在哈佛学院（Harvard College）获得生物化学学士学位。他在华盛顿大学（University of Washington）完成内科住院医师和医疗肿瘤学研究金。
Jonathan G. Drachman has served as a director and the Chief Executive Officer of Neoleukin since November 2018. From November 2004 to May 2018 Dr. Drachman held several positions at Seagen Inc., culminating in the position of Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004 he was a faculty member in the Division of Hematology at the University of Washington, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors of Harpoon Therapeutics, Inc. and Calithera Biosciences, Inc. Dr. Drachman received his M.D. at Harvard Medical School and his A.B. in Biochemistry from Harvard College. He completed his residency in internal medicine and a fellowship in medical oncology at the University of Washington.- JonathanG.Drachman自2018年11月起担任Neoleukin的董事兼首席执行官。从2004年11月到2018年5月，Drachman博士在SeattleGenetics，Inc.担任过多个职位，最终担任研究与开发首席医疗官兼执行Vice President。从1998年到2004年，他曾担任华盛顿大学（University of Washington）的血液学部门的教员，以及普吉特海湾血液中心（Puget Sound Blood Center）的研究和教育部门的高级研究员。他目前任职于HarpoonTherapeutics，Inc.和CalitheraBiosciences，Inc.的董事会。Drachman博士在哈佛医学院（Harvard Medical School）获得医学博士学位，并在哈佛学院（Harvard College）获得生物化学学士学位。他在华盛顿大学（University of Washington）完成内科住院医师和医疗肿瘤学研究金。
- Jonathan G. Drachman has served as a director and the Chief Executive Officer of Neoleukin since November 2018. From November 2004 to May 2018 Dr. Drachman held several positions at Seagen Inc., culminating in the position of Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004 he was a faculty member in the Division of Hematology at the University of Washington, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors of Harpoon Therapeutics, Inc. and Calithera Biosciences, Inc. Dr. Drachman received his M.D. at Harvard Medical School and his A.B. in Biochemistry from Harvard College. He completed his residency in internal medicine and a fellowship in medical oncology at the University of Washington.
- Robert Ho
Robert Ho自2020年3月起担任公司首席财务官。在加入我们之前，何先生自2016年1月起在肾脏透析服务提供商DaVitaInc.担任多个职位，包括最近担任高级财务总监。在此之前，何先生于2007年至2014年担任一家私有公司的战略财务顾问。Ho先生还从2004年3月到2007年2月在摩根士丹利担任多个职位，包括最近担任医疗保健投资银行部门的副总裁。何先生拥有圣母大学的工商管理学士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
Robert Ho has served as Third Harmonic Bio, Inc. Chief Financial Officer since March 2022. Prior to joining Third Harmonic Bio, Inc., Mr. Ho worked at Neoleukin Therapeutics, Inc. serving as Chief Financial Officer from March 2020 to March 2022. Mr. Ho served in various positions at Davita Inc., including most recently as Senior Finance Director from January 2016 to March 2020. Prior to that, and a one-year break in service, Mr. Ho served as Strategic Financial Advisor to a privately owned company from February 2007 to December 2014. Mr. Ho also served in various positions at Morgan Stanley from March 2004 to February 2007 including most recently as a Vice President in the Healthcare Investment Banking Division. Mr. Ho holds a B.B.A. in accountancy and computer applications from the University of Notre Dame and an M.B.A. from the University of Virginia Darden School of Business.- Robert Ho自2020年3月起担任公司首席财务官。在加入我们之前，何先生自2016年1月起在肾脏透析服务提供商DaVitaInc.担任多个职位，包括最近担任高级财务总监。在此之前，何先生于2007年至2014年担任一家私有公司的战略财务顾问。Ho先生还从2004年3月到2007年2月在摩根士丹利担任多个职位，包括最近担任医疗保健投资银行部门的副总裁。何先生拥有圣母大学的工商管理学士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
- Robert Ho has served as Third Harmonic Bio, Inc. Chief Financial Officer since March 2022. Prior to joining Third Harmonic Bio, Inc., Mr. Ho worked at Neoleukin Therapeutics, Inc. serving as Chief Financial Officer from March 2020 to March 2022. Mr. Ho served in various positions at Davita Inc., including most recently as Senior Finance Director from January 2016 to March 2020. Prior to that, and a one-year break in service, Mr. Ho served as Strategic Financial Advisor to a privately owned company from February 2007 to December 2014. Mr. Ho also served in various positions at Morgan Stanley from March 2004 to February 2007 including most recently as a Vice President in the Healthcare Investment Banking Division. Mr. Ho holds a B.B.A. in accountancy and computer applications from the University of Notre Dame and an M.B.A. from the University of Virginia Darden School of Business.
- Holly Vance
Holly Vance自2020年10月起担任我们的总法律顾问，自2021年3月起担任秘书。从2015年9月至2020年10月，万斯女士担任比尔与梅琳达·盖茨基金会战略投资基金的副总法律顾问，一个私人基金会的工作重点是在全球范围内提高医疗保健和减少贫穷，并在美国扩大教育机会和获得信息技术的机会。在此之前，她曾于2005年10月至2015年9月担任律师事务所K&L Gates的合伙人。万斯女士获得了细胞与分子生物学和药学理学学士学位，药学博士学位和法学博士学位，均来自华盛顿大学。
Holly Vance has served as our General Counsel since October 2020 and Secretary since March 2021. From September 2015 until October 2020 Ms. Vance served as Associate General Counsel for the Strategic Investment Fund at the Bill & Melinda Gates Foundation, a private foundation focused on enhancing healthcare and reducing poverty across the globe and expanding educational opportunities and access to information technology in the United States. Prior to that she served as a Partner at the law firm, K&L Gates, where she worked from October 2005 until September 2015. Ms. Vance received Bachelor of Science degrees in Cell and Molecular Biology and Pharmacy, a Doctor of Pharmacy, and a Juris Doctorate, all from the University of Washington.- Holly Vance自2020年10月起担任我们的总法律顾问，自2021年3月起担任秘书。从2015年9月至2020年10月，万斯女士担任比尔与梅琳达·盖茨基金会战略投资基金的副总法律顾问，一个私人基金会的工作重点是在全球范围内提高医疗保健和减少贫穷，并在美国扩大教育机会和获得信息技术的机会。在此之前，她曾于2005年10月至2015年9月担任律师事务所K&L Gates的合伙人。万斯女士获得了细胞与分子生物学和药学理学学士学位，药学博士学位和法学博士学位，均来自华盛顿大学。
- Holly Vance has served as our General Counsel since October 2020 and Secretary since March 2021. From September 2015 until October 2020 Ms. Vance served as Associate General Counsel for the Strategic Investment Fund at the Bill & Melinda Gates Foundation, a private foundation focused on enhancing healthcare and reducing poverty across the globe and expanding educational opportunities and access to information technology in the United States. Prior to that she served as a Partner at the law firm, K&L Gates, where she worked from October 2005 until September 2015. Ms. Vance received Bachelor of Science degrees in Cell and Molecular Biology and Pharmacy, a Doctor of Pharmacy, and a Juris Doctorate, all from the University of Washington.
- Carl Walkey
Carl Walkey自2021年2月起担任公司发展高级副总裁。在此之前，他于2019年7月至2021年2月担任公司发展副总裁。在进入Neoleukin Therapeutics之前，Walkey博士于2016年5月至2019年7月担任华盛顿大学蛋白质设计研究所高级研究员。在此之前，他于2014年5月至2015年9月担任Ansible Marketing的创始合伙人。Walkey博士获得了Carleton大学的工程物理学工程学士学位和多伦多大学的生物工程和生物医学工程博士学位。
Carl Walkey has served as Senior Vice President of Corporate Development since February 2021. Prior to that he served as Vice President of Corporate Development from July 2019 until February 2021. Before coming to Neoleukin Therapeutics, Dr. Walkey was a Senior Fellow at the University of Washington, Institute for Protein Design from May 2016 until July 2019. Prior to that, he served as Founding Partner at Ansible Marketing from May 2014 until September 2015. Dr Walkey received a Bachelor of Engineering in Engineering Physics from Carleton University and a Ph.D. in Bioengineering and Biomedical Engineering from the University of Toronto.- Carl Walkey自2021年2月起担任公司发展高级副总裁。在此之前，他于2019年7月至2021年2月担任公司发展副总裁。在进入Neoleukin Therapeutics之前，Walkey博士于2016年5月至2019年7月担任华盛顿大学蛋白质设计研究所高级研究员。在此之前，他于2014年5月至2015年9月担任Ansible Marketing的创始合伙人。Walkey博士获得了Carleton大学的工程物理学工程学士学位和多伦多大学的生物工程和生物医学工程博士学位。
- Carl Walkey has served as Senior Vice President of Corporate Development since February 2021. Prior to that he served as Vice President of Corporate Development from July 2019 until February 2021. Before coming to Neoleukin Therapeutics, Dr. Walkey was a Senior Fellow at the University of Washington, Institute for Protein Design from May 2016 until July 2019. Prior to that, he served as Founding Partner at Ansible Marketing from May 2014 until September 2015. Dr Walkey received a Bachelor of Engineering in Engineering Physics from Carleton University and a Ph.D. in Bioengineering and Biomedical Engineering from the University of Toronto.